SUBSCRIBE
SUBSCRIBE

REGENXBIO

NEWS
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
BioCapital
REGENXBIO Banks $70.5 Million As Gene Therapy Enjoys Revival
May 20, 2015
 · 
4 min read
Load More
JOBS
IN THE PRESS
Press Releases
AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program
January 13, 2025
 · 
7 min read
BioCapital
REGENXBIO to Participate in Upcoming May 2024 Investor Conferences
May 10, 2024
 · 
1 min read
Business
REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights
May 8, 2024
 · 
13 min read
Business
REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights
May 1, 2024
 · 
1 min read
BioCapital
REGENXBIO to Participate in Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
April 24, 2024
 · 
1 min read
Drug Development
REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD
March 28, 2024
 · 
8 min read
BioCapital
REGENXBIO to Participate in Cantor Fitzgerald’s Virtual DMD and Other Dystrophy Days
March 27, 2024
 · 
1 min read
BioCapital
REGENXBIO to Participate in Upcoming March 2024 Investor Conferences
March 11, 2024
 · 
1 min read
BioCapital
REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants
March 6, 2024
 · 
6 min read
Policy
Regenxbio Announces New Positive Initial Efficacy Data From Affinity Duchenne® Trial
March 5, 2024
 · 
11 min read
Load More